ABT · Full Picture

ABBOTT LABORATORIES — the full picture

Earnings window · 2026-07-28 to 2026-11-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Exact Sciences Acquisition · M&A and divestituresPriority 88
    +2.7% revenue; 2 sources (press_release, sec_filing); 2 forward row(s); structured_verified
    Abbott completed the acquisition of Exact Sciences on March 23, 2026 for approximately $20.6 billion.
  2. Gross Margin Drivers · Gross marginPriority 87
    -35.4% operating_income; 3 sources (news, sec_filing, transcript); 5 forward row(s); quote_verified
    Abbott’s estimated annual amortization expense for intangible assets: approximately $2.6 billion in 2026, $2.3 billion in 2027, $1.8 billion in 2028, $1.7 billion in 2029, and $1.5 billion in 2030.
  3. Operating Expense Trends · Operating expenses (SG&A)Priority 86
    -63.4% operating_income; 2 sources (press_release, sec_filing); 5 forward row(s); structured_verified
    Abbott’s estimated annual amortization expense for intangible assets is approximately $3.0 billion in 2026, $2.7 billion in 2027, $2.1 billion in 2028, $2.1 billion in 2029, and $1.9 billion in 2030.
  4. Revenue Performance and Mix · Revenue growth & mixPriority 85
    +13.4% revenue (realized); 4 sources (news, press_release, sec_filing, transcript); 5 forward row(s); quote_verified
    Analysts expect Abbott Laboratories to report Q3 EPS of $1.41 on $12.99 billion revenue for its Q3 earnings to be released on October 21, 2026.
  5. Debt and Liquidity Position · Liquidity & cash positionPriority 83
    -20.7% liability (realized); structured_verified
    The Exact Sciences acquisition was funded primarily through the issuance of $20.0 billion of long-term debt in March 2026, with the remainder funded by cash on hand.
  6. Order Backlog and Book-to-Bill · Demand, orders & backlogPriority 80
    +40.5% revenue; 1 forward row(s); quote_verified
    Abbott expected to recognize revenue on approximately $6.2 billion of remaining performance obligations in the Diagnostic Products segment as of September 30, 2026.
  7. Guidance / Outlook · Guidance & outlookPriority 79
    +8.1% revenue; 3 sources (news, press_release, transcript); 6 forward row(s); quote_verified
    Abbott projects full-year 2026 comparable sales growth to be approximately 6.0 percent
  8. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 76
    -17.9% revenue; 2 sources (news, press_release); 2 forward row(s); quote_verified
    The separation of Abbott's Nutrition business is expected to be completed by the end of 2027.
  9. Operating Cash Flow and Capex · UnclassifiedPriority 72
    -18.9% cash (realized); quote_verified
    Net cash used in investing activities for the six months ended June 30, 2026: $(20,997) million and for the six months ended June 30, 2025: $(1,052) million.
  10. Operating Income and Margins · Operating income & profitabilityPriority 69
    -8.9% operating_income (realized); 3 sources (news, press_release, sec_filing); quote_verified
    Third-quarter operating earnings (Operating Earnings) 3Q26: $1,358 million, down 34.0% vs 3Q25
  11. Infant Formula Litigation · Litigation & settlementsPriority 68
    -2.7% net_income; 4 sources (news, press_release, sec_filing, transcript); 7 forward row(s); quote_verified
    Mississippi Attorney General Lynn Fitch announced a $384 million settlement with Abbott Laboratories over allegations regarding infant formula and nutritional therapy products manufactured in plants that failed safety standards.
  12. Research and Development Investment · R&D investmentPriority 64
    -2.9% operating_income (realized); 2 sources (sec_filing, transcript); 1 forward row(s); structured_verified
    Abbott’s R&D spending averaged around $1.7 billion to $1.8 billion before COVID, is crossing $3 billion this year, and is expected to increase next year.

Threads by pillar

Revenue & Demand Priority 94 · 13 threads

Costs & Margins Priority 95 · 7 threads

Capital & Balance Sheet Priority 90 · 5 threads

Strategy & Portfolio Priority 91 · 10 threads

Legal, Regulatory & Policy Priority 82 · 8 threads

Guidance & Outlook Priority 79 · 1 thread

Macro & Market Conditions Priority 53 · 5 threads

Unclassified Priority 95 · 5 threads

Expected impact by metric

metricforward netforward grossrealized
operating_income-101.5%+101.5%-26.1%
revenue+33.5%+71.0%+33.5%
net_income-7.9%+7.9%-21.5%
liability-1.7%+1.7%-43.5%
cash-1.4%+1.4%-28.6%
margin+0.5%+0.5%-7.7%
assets——+45.5%